S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

$10.87
0.00 (0.00%)
(As of 04:37 PM ET)
Today's Range
$10.41
$10.95
50-Day Range
$8.49
$12.24
52-Week Range
$3.80
$20.00
Volume
21,209 shs
Average Volume
33,772 shs
Market Capitalization
$64.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.33

Curis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
248.3% Upside
$37.33 Price Target
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Curis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.92) to ($4.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

Medical Sector

392nd out of 939 stocks

Biological Products, Except Diagnostic Industry

60th out of 154 stocks

CRIS stock logo

About Curis Stock (NASDAQ:CRIS)

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CRIS Stock Price History

CRIS Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Curis Inc Q4 sales decline
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Curis Provides Fourth Quarter 2023 Business Update
Curis's Earnings: A Preview
Curis Announces Three Presentations at ASH
Curis Inc CRIS
See More Headlines
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
49
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$37.33
High Stock Price Target
$60.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+243.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,410,000.00
Net Margins
-473.04%
Pretax Margin
-473.04%

Debt

Sales & Book Value

Annual Sales
$10.02 million
Book Value
$3.34 per share

Miscellaneous

Free Float
5,610,000
Market Cap
$64.02 million
Optionable
Optionable
Beta
3.76

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

CRIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Curis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings
or view top-rated stocks.

What is Curis' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they anticipate the company's stock price to reach $37.33 in the next year. This suggests a possible upside of 248.3% from the stock's current price.
View analysts price targets for CRIS
or view top-rated stocks among Wall Street analysts.

How have CRIS shares performed in 2024?

Curis' stock was trading at $12.75 on January 1st, 2024. Since then, CRIS shares have decreased by 15.9% and is now trading at $10.72.
View the best growth stocks for 2024 here
.

Are investors shorting Curis?

Curis saw a drop in short interest in March. As of March 15th, there was short interest totaling 47,900 shares, a drop of 14.5% from the February 29th total of 56,000 shares. Based on an average trading volume of 35,000 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the company's stock are short sold.
View Curis' Short Interest
.

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRIS earnings forecast
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.91) by $0.12. The biotechnology company had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 169.22%. During the same period last year, the company posted ($2.40) EPS.

When did Curis' stock split?

Shares of Curis reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Who are Curis' major shareholders?

Curis' stock is owned by a number of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.82%), Vanguard Group Inc. (3.54%), Vanguard Group Inc. (3.54%), Arnhold LLC (0.28%), Northern Trust Corp (0.27%) and a16z Perennial Management L.P. (0.11%).
View institutional ownership trends
.

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRIS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners